Boor Kathryn Jean 4
4 · Sarepta Therapeutics, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sarepta (SRPT) Director Kathryn Boor Receives 16,875 RSU Award
What Happened
- Kathryn Jean Boor, a director of Sarepta Therapeutics (SRPT), was granted 16,875 restricted stock units (RSUs) on 2026-06-04. The grant is reported as an award (transaction code A); no purchase price is applicable (N/A). RSUs represent the right to receive one share of common stock per RSU when they vest. The Form 4 was filed on 2026-06-05.
Key Details
- Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-05)
- Type/code: Award/Grant (A)
- Shares/units granted: 16,875 RSUs
- Price: N/A (RSU award, not an open-market trade)
- Vesting: RSUs vest on the earlier of the one-year anniversary of the grant and the next annual meeting of stockholders that is at least 50 weeks after the prior year’s meeting (per footnote)
- Shares owned after transaction: Not specified in the provided filing extract
- Filing timeliness: Filed the next day (appears timely; not marked late)
Context
- RSU grants are a form of compensation/retention for directors and do not represent an immediate market purchase or sale. The RSUs will convert to actual shares only upon meeting the vesting conditions; any future sale or withholding upon vesting would be reported separately.
Insider Transaction Report
Form 4
Boor Kathryn Jean
Director
Transactions
- Award
Common Stock
[F1]2026-06-04+16,875→ 25,138 total
Footnotes (1)
- [F1]The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Kathryn Boor|2026-06-05